University of Oulu

KOIVUROVA, O.-P., KOSKELA, R., BLOMSTER, T., ALA-RÄMI, A., LUMME, H., KETTUNEN, O., HUKKANEN, J., KARTTUNEN, T. J., MÄKINEN, M., RONKAINEN, J., & SYRJÄNEN, K. (2021). Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection in Gastroscopy Referral Patients: Clinical Validation of the New-Generation GastroPanel® Test. Anticancer Research, 41(11), 5527–5537.

Serological biomarker panel in diagnosis of atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients : clinical validation of the new-generation GastroPanel® test

Saved in:
Author: Koivurova, Olli-Pekka1; Koskela, Ritva2; Blomster, Timo2;
Organizations: 1Department of Endoscopy, Terveystalo Medical Center, Oulu, Finland
2Research Unit of Internal Medicine, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland
3Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland
4Department of Pathology, Oulu University Hospital, Oulu, Finland
5Center for Life Course Health Research, University of Oulu, Oulu, Finland
6Primary Health Care Center, Tornio, Finland
7Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
8SMW Consultants, Ltd., Kaarina, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 1.2 MB)
Persistent link:
Language: English
Published: International Institute of Anticancer Research, 2021
Publish Date: 2022-01-05


Background/Aim: Prompted by the increasing demand of non-invasive diagnostic tools for screening of gastric cancer (GC) risk conditions, i.e., atrophic gastritis (AG) and Helicobacter pylori (Hp) infection, the GastroPanel® test (GP: biomarker panel of PGI, PGII, G‐17, Hp IgG ELISA) that was developed in the early 2000’s, was recently updated to a new-generation (unified GP) test version. This clinical validation study evaluated the diagnostic accuracy of the new-generation GP test in detection of AG and Hp among gastroscopy referral patients in a University Clinic. Patients and Methods: Altogether, 522 patients were enrolled among the patients referred for gastroscopy at the Gastro Center, Oulu University Hospital (OUH). All patients underwent gastroscopy with biopsies classified using the Updated Sydney System (USS), and blood sampling for GP testing. Results: Biopsy-confirmed AG was found in 10.2% (53/511) of the patients. The overall agreement between the GP and the USS classification was 92.4% (95%CI=90.0‐94.6%), with the weighted kappa (κw) of 0.861 (95%CI=0.834‐0.883). In ROC analysis using moderate/severe AG of the corpus (AGC2+) as the endpoint, AUC=0.952 (95%CI=0.891‐1.000) and AUC=0.998 (95%CI=0.996‐1.000) for PGI and PGI/PGII, respectively. Hp IgG antibody ELISA detected biopsy-confirmed Hp-infection with AUC=0.993 (95%CI=0.987‐0.999). Conclusion: The new generation GastroPanel® is a precise test for non-invasive diagnosis of atrophic gastritis and Hp-infection in dyspeptic patients referred for diagnostic gastroscopy.

see all

Series: Anticancer research
ISSN: 0250-7005
ISSN-E: 1791-7530
ISSN-L: 0250-7005
Volume: 41
Issue: 11
Pages: 5527 - 5537
DOI: 10.21873/anticanres.15366
Type of Publication: A1 Journal article – refereed
Field of Science: 3111 Biomedicine
3121 General medicine, internal medicine and other clinical medicine
Funding: This study was funded by a non-restricted research grant from Biohit Oyj (Helsinki, Finland).
Copyright information: Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. Published in this repository with the kind permission of the publisher.